Evidence map›Paper›PMID 39225558›Full record

ArticleCancer research communications2024

MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.

Alexandra Blackman, Amy C Rees, Robert R Bowers, Christian M Jones, Silvia G Vaena, Madison A Clark, Shelby Carter, Evan D Villamor, Della Evans, Anthony J Emanuel and 9 more

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Alexandra Blackman *Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-8841-124X
Amy C Rees *Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0004-7899-9528
Robert R Bowers *Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-1873-2114
Christian M Jones *Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-0914-2967
Silvia G VaenaHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0004-5811-1659
Madison A ClarkDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0000-0319-1656
Shelby CarterDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0000-3826-005X
Evan D VillamorDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0005-6095-3748
Della EvansDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0000-8311-8933
Anthony J EmanuelDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-2139-6422
George FullbrightDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-0321-0559
Matthew S O'MalleyDepartment of Medical Sciences, Indiana University Bloomington, Bloomington, Indiana.ORCID 0009-0001-2075-8519
Richard L CarpenterDepartment of Medical Sciences, Indiana University Bloomington, Bloomington, Indiana.ORCID 0000-0001-9986-6493
David T LongDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-9232-0316
Laura S SpruillDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-1895-5203
Martin J RomeoHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-7941-1862
Brian C OrrDepartment of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-0158-1575
Kristi L HelkeDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0001-9746-0764
Joe R DelaneyDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-8978-5961

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
Connecting BRCA1 functions with DNA crosslink sensitivityR35GM119512 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LONG, DAVID THOMAS · 2016 to 2025
$3.9M
Cellular, Biochemical and Molecular Sciences Training Program: Developing the skills and expertise needed for a changing biomedical landscapeT32GM132055 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Amy D Bradshaw, John P O'Bryan · 2019 to 2026
$3.9M
Tumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genesDP2CA280626 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Joe R Delaney · 2022 to 2026
$2.3M
Copy Number Alterations in Low Mutation CancerR00CA207729 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DELANEY, JOE R · 2019 to 2021
$730k
Functional interactions between AKT and HSF-1 in breast cancer progressionK22CA207575 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CARPENTER, RICHARD L · 2017 to 2019
$486k
Copy Number Alterations in Low Mutation CancerK99CA207729 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DELANEY, JOE R · 2017 to 2018
$230k
NCI NIH HHS DP2 CA280626NCI NIH HHS K22 CA207575NCI NIH HHS K99 CA207729NCI NIH HHS P30 CA138313NCI NIH HHS R00 CA207729NIGMS NIH HHS P20 GM103499NIGMS NIH HHS R35 GM119512NIGMS NIH HHS T32 GM132055
6 · The paper itself

Abstract

Genetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment are understood. MYC, an oncogene, is amongst the most amplified genes in high-grade serous ovarian cancer (HGSOC), but it has not previously been utilized to drive HGSOC GEMMs. We coupled Myc and dominant-negative mutant p53-R270H with a fallopian tube epithelium (FTE)-specific promoter Ovgp1 to generate a new GEMM of HGSOC. Female mice developed lethal cancer at an average of 14.5 months. Histopathologic examination of mice revealed HGSOC characteristics, including nuclear p53 and nuclear MYC in clusters of cells within the FTE and ovarian surface epithelium. Unexpectedly, nuclear p53 and MYC clustered cell expression was also identified in the uterine luminal epithelium, possibly from intraepithelial metastasis from the FTE. Extracted tumor cells exhibited strong loss of heterozygosity at the p53 locus, leaving the mutant allele. Copy-number alterations in these cancer cells were prevalent, disrupting a large fraction of genes. Transcriptome profiles most closely matched human HGSOC and serous endometrial cancer. Taken together, these results demonstrate that the Myc and Trp53-R270H transgenes were able to recapitulate many phenotypic hallmarks of HGSOC through the utilization of strictly human-mimetic genetic hallmarks of HGSOC. This new mouse model enables further exploration of ovarian cancer pathogenesis, particularly in the 50% of HGSOC which lack homology-directed repair mutations. Histologic and transcriptomic findings are consistent with the hypothesis that uterine serous cancer may originate from the FTE. SIGNIFICANCE: Mouse models using transgenes which generate spontaneous cancers are essential tools to examine the etiology of human diseases. Here, the first Myc-driven spontaneous model is described as a valid HGSOC model. Surprisingly, aspects of uterine serous carcinoma were also observed in this model.

Indexed as

Cystadenocarcinoma, SerousDisease Models, AnimalOvarian NeoplasmsProto-Oncogene Proteins c-mycTumor Suppressor Protein p53Uterine NeoplasmsAnimalsFemaleHumansMiceMice, TransgenicMyc protein, mouseProto-Oncogene Proteins c-mycTrp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID39225558
PMCPMC11425777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.